Ki-67 表达增加是结直肠癌患者预后不良的标志物：一项荟萃分析。

Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis.

机构信息

Department of Internal Medicine, The Affiliated Chencun Hospital of Shunde Hospital, Southern Medical University, Shunde, 528313, Guangdong, China.

出版信息

BMC Cancer. 2019 Feb 6;19(1):123. doi: 10.1186/s12885-019-5324-y.

BACKGROUND

The prognostic value of Ki-67 expression in colorectal cancer patients was controversial. Therefore, this meta analysis was conducted to ascertain the prognostic value of Ki-67 expression in colorectal cancer patients.

METHODS

The electronic databases, including EMBASE, PubMed, Cochrane Library and Web of Knowledge database, were searched from January 1970 to July 2017. The pooled hazard ratios and 95% confidence intervals were calculated to evaluate the prognostic value of Ki-67 expression for colorectal cancer patients.

RESULTS

Totally 34 eligible studies and 6180 colorectal cancer patients were included in the present meta analysis. The pooled hazard ratios were 1.54(95% CI 1.17-2.02, P = 0.005) for overall survival and 1.43(1.12-1.83, P = 0.008) for disease free survival in univariate analysis. After adjustment of other prognostic factors, the pooled HR was 1.50(95% CI 1.02-2.22, P = 0.03) for overall survival in multivariate analysis.

CONCLUSION

The present meta analysis demonstrated that high Ki-67 expression is significantly correlated with poor overall survival and disease free survival, indicating that high Ki-67 expression may serve as a valuable predictive method for poor prognosis of colorectal cancer patients.

背景

Ki-67 表达在结直肠癌患者中的预后价值存在争议。因此，进行了这项荟萃分析，以确定 Ki-67 表达在结直肠癌患者中的预后价值。

方法

检索了电子数据库，包括 EMBASE、PubMed、Cochrane Library 和 Web of Knowledge 数据库，检索时间为 1970 年 1 月至 2017 年 7 月。计算合并的风险比和 95%置信区间，以评估 Ki-67 表达对结直肠癌患者的预后价值。

结果

本荟萃分析共纳入 34 项研究和 6180 例结直肠癌患者。单因素分析显示，Ki-67 表达的总生存率合并风险比为 1.54（95%CI 1.17-2.02，P=0.005），无病生存率合并风险比为 1.43（1.12-1.83，P=0.008）。在调整其他预后因素后，多因素分析中 Ki-67 表达的合并 HR 为 1.50（95%CI 1.02-2.22，P=0.03）。